VERTEX PHARMACEUTICALS INC (VRTX) Stock Fundamental Analysis

NASDAQ:VRTX • US92532F1003

491.47 USD
+26.45 (+5.69%)
At close: Feb 13, 2026
494.561 USD
+3.09 (+0.63%)
After Hours: 2/13/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to VRTX. VRTX was compared to 523 industry peers in the Biotechnology industry. While VRTX has a great profitability rating, there are some minor concerns on its financial health. VRTX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • VRTX had positive earnings in the past year.
  • In the past year VRTX had a positive cash flow from operations.
  • In multiple years VRTX reported negative net income over the last 5 years.
  • In multiple years VRTX reported negative operating cash flow during the last 5 years.
VRTX Yearly Net Income VS EBIT VS OCF VS FCFVRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • The Return On Assets of VRTX (14.78%) is better than 95.60% of its industry peers.
  • VRTX has a better Return On Equity (21.22%) than 96.18% of its industry peers.
  • VRTX has a Return On Invested Capital of 17.58%. This is amongst the best in the industry. VRTX outperforms 97.13% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for VRTX is in line with the industry average of 18.27%.
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROIC 17.58%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)19.67%
ROIC(5y)20.26%
VRTX Yearly ROA, ROE, ROICVRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.35%, VRTX belongs to the top of the industry, outperforming 96.18% of the companies in the same industry.
  • The Operating Margin of VRTX (38.70%) is better than 98.09% of its industry peers.
  • In the last couple of years the Operating Margin of VRTX has grown nicely.
  • The Gross Margin of VRTX (86.28%) is better than 89.10% of its industry peers.
  • In the last couple of years the Gross Margin of VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
VRTX Yearly Profit, Operating, Gross MarginsVRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so VRTX is still creating some value.
  • There is no outstanding debt for VRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VRTX Yearly Shares OutstandingVRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
VRTX Yearly Total Debt VS Total AssetsVRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • VRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.43
WACC12.26%
VRTX Yearly LT Debt VS Equity VS FCFVRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.36 indicates that VRTX has no problem at all paying its short term obligations.
  • The Current ratio of VRTX (2.36) is worse than 71.89% of its industry peers.
  • VRTX has a Quick Ratio of 2.00. This is a normal value and indicates that VRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of VRTX (2.00) is worse than 74.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2
VRTX Yearly Current Assets VS Current LiabilitesVRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 6248.28% over the past year.
  • VRTX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 12.27% yearly.
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.80% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 9.15% on average over the next years. This is quite good.
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%

3.3 Evolution

  • The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
VRTX Yearly Revenue VS EstimatesVRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
VRTX Yearly EPS VS EstimatesVRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 20 30 40

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • VRTX is valuated quite expensively with a Price/Earnings ratio of 26.70.
  • 93.69% of the companies in the same industry are more expensive than VRTX, based on the Price/Earnings ratio.
  • VRTX is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.97, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 24.11, VRTX is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, VRTX is valued cheaper than 92.93% of the companies in the same industry.
  • VRTX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 27.96, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 26.7
Fwd PE 24.11
VRTX Price Earnings VS Forward Price EarningsVRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VRTX indicates a rather cheap valuation: VRTX is cheaper than 93.31% of the companies listed in the same industry.
  • VRTX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. VRTX is cheaper than 93.12% of the companies in the same industry.
Industry RankSector Rank
P/FCF 37.37
EV/EBITDA 23.58
VRTX Per share dataVRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • VRTX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.49
PEG (5Y)2.18
EPS Next 2Y11.49%
EPS Next 3Y10.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • VRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

VERTEX PHARMACEUTICALS INC

NASDAQ:VRTX (2/13/2026, 8:00:01 PM)

After market: 494.561 +3.09 (+0.63%)

491.47

+26.45 (+5.69%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-12
Earnings (Next)05-04
Inst Owners97.56%
Inst Owner Change-1.78%
Ins Owners0.13%
Ins Owner Change7.12%
Market Cap124.70B
Revenue(TTM)N/A
Net Income(TTM)3.68B
Analysts80
Price Target532.5 (8.35%)
Short Float %1.75%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.29%
Min EPS beat(2)3.12%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.92%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.45%
EPS beat(8)5
Avg EPS beat(8)-64.05%
EPS beat(12)7
Avg EPS beat(12)-42.39%
EPS beat(16)10
Avg EPS beat(16)-31.28%
Revenue beat(2)1
Avg Revenue beat(2)-0.58%
Min Revenue beat(2)-1.21%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.82%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.69%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)7
Avg Revenue beat(16)-0.32%
PT rev (1m)6.28%
PT rev (3m)8.26%
EPS NQ rev (1m)-0.16%
EPS NQ rev (3m)0.75%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.78%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)-0.15%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE 26.7
Fwd PE 24.11
P/S 10.64
P/FCF 37.37
P/OCF 33.54
P/B 7.2
P/tB 7.89
EV/EBITDA 23.58
EPS(TTM)18.41
EY3.75%
EPS(NY)20.39
Fwd EY4.15%
FCF(TTM)13.15
FCFY2.68%
OCF(TTM)14.65
OCFY2.98%
SpS46.21
BVpS68.26
TBVpS62.28
PEG (NY)2.49
PEG (5Y)2.18
Graham Number168.15
Profitability
Industry RankSector Rank
ROA 14.78%
ROE 21.22%
ROCE 22.25%
ROIC 17.58%
ROICexc 25.42%
ROICexgc 28.48%
OM 38.7%
PM (TTM) 31.35%
GM 86.28%
FCFM 28.47%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)19.67%
ROIC(5y)20.26%
ROICexc(3y)48.65%
ROICexc(5y)54.9%
ROICexgc(3y)69.59%
ROICexgc(5y)85.25%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score7
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 189.83%
Cap/Sales 3.25%
Interest Coverage 374.91
Cash Conversion 78.49%
Profit Quality 90.81%
Current Ratio 2.36
Quick Ratio 2
Altman-Z N/A
F-Score7
WACC12.26%
ROIC/WACC1.43
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6248.28%
EPS 3Y7.33%
EPS 5Y12.27%
EPS Q2Q%26.38%
EPS Next Y10.74%
EPS Next 2Y11.49%
EPS Next 3Y10.83%
EPS Next 5Y11.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%9.55%
Revenue Next Year8.7%
Revenue Next 2Y9.21%
Revenue Next 3Y9.38%
Revenue Next 5Y9.15%
EBIT growth 1Y5.79%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year824.9%
EBIT Next 3Y127.59%
EBIT Next 5Y70.14%
FCF growth 1Y-20.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.14%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / VRTX FAQ

Can you provide the ChartMill fundamental rating for VERTEX PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to VRTX.


What is the valuation status for VRTX stock?

ChartMill assigns a valuation rating of 5 / 10 to VERTEX PHARMACEUTICALS INC (VRTX). This can be considered as Fairly Valued.


Can you provide the profitability details for VERTEX PHARMACEUTICALS INC?

VERTEX PHARMACEUTICALS INC (VRTX) has a profitability rating of 7 / 10.


What is the valuation of VERTEX PHARMACEUTICALS INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for VERTEX PHARMACEUTICALS INC (VRTX) is 26.7 and the Price/Book (PB) ratio is 7.2.


How financially healthy is VERTEX PHARMACEUTICALS INC?

The financial health rating of VERTEX PHARMACEUTICALS INC (VRTX) is 5 / 10.